The PRWIRE Press Releases https:// 2018-11-12T22:36:44Z Pharma veterans guide next generation of researchers and entrepreneurs 2018-11-12T22:36:44Z pharma-veterans-guide-next-generation-of-researchers-and-entrepreneurs Pharmaceutical sector leaders and experts joined government and NGO representatives to share their collective wisdom with young researchers, entrepreneurs and industry professionals at The Bridge Program’s Residential Training Program last week. The Bridge Program was launched in 2017 to boost the commercial output of Australian pharmaceutical research by providing face-to-face and online training in research translation and the commercialisation of medicines. Run by Queensland University of Technology, it involves a consortium of 15 pharmaceutical companies, universities and industry associations, and selects 100 participants from across Australia annually. The three-day Residential Training Program, now in its second year, involved workshops, case studies, networking opportunities and presentations from national and international guests, including CEO of Innovation and Science Australia, Charlie Day, Amgen’s VP of Global Health Economics, Martin Zagari, and Member for Bennelong John Alexander MP, to name a few. Mr Zagari presented on the value of medicines in healthcare and society, which he said was being challenged by a shift in focus from value to cost. He said fixating on initial investment costs was misleading, as almost all investments in medicines became cost neutral and most became cost saving, yielding enormous value. “In the US, every dollar spent on medicines for congenital heart failure returned $3-$10 in savings,” he said. “Every 1% reduction in cancer mortality would deliver $500 billion in savings globally. We need to consider what the cost of not improving treatments will be.” Mundipharma’s Director of Corporate Affairs, Meriana Baxter, chaired a session that tasked cross-functional teams with delivering a mock pitch to industry executives role-playing as venture capital investors. The “investors” were impressed with what the teams achieved in a short timeframe, but provided detailed advice on how they could cut through more effectively. My Linh Kha, Executive Director and General Manager of Amgen Australia and New Zealand, spoke of the promise of the medical discoveries that may be made by the attendees, and the benefits they may have on patients in the future. “I am so proud of the collective knowledge and experience that can be leveraged through this program,” Ms Kha said. “I wish an opportunity like this existed when I began my career, and I am sure we’ll be seeing the impact of this effort for years and decades to come.” Mr Alexander closed the program with a reflection on his time representing his electorate and the home of “Pill Hill”. “I’m so lucky to have had the opportunity to meet so many in this industry,” Mr Alexander said. “You are all motivated by the common goal of improving quality of life, extending life and addressing illness.” The program’s final event for 2018 will be held at Queensland University of Technology on 13 December with keynote speaker Professor Ian Frazer, who co-invented the technology enabling human papilloma virus (HPV) vaccines. More information on The Bridge Program can be found here: research.qut.edu.au/bridge/, including a full agenda for the Residential Training Program. The Bridge Program collaborators include Mundipharma, MTPConnect, AbbVie, Amgen, The Australian Private Equity and Venture Capital Association Limited (AVCAL), Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL, Janssen-Cilag, Macquarie University, Medical Research Commercialisation Fund, Medicines Australia, MSD, Novartis and Pfizer. G MEDICAL PURCHASES TELERHYTHMICS LLC, MEDICAL DIAGNOSTIC MONITORING SERVICE PROVIDER 2018-11-02T02:32:40Z g-medical-purchases-telerhythmics-llc-medical-diagnostic-monitoring-service-provider Expands infrastructure to increase nationwide footprint and services for remote vital signs monitoring healthcare services in the USA Provides additional capacity, access to technologies and payer network November 2, 2018 - Sydney, Australia – Mobile and e-Health company G Medical Innovations Holdings Ltd (G Medical or the Company) (ASX: GMV) is pleased to announce that its wholly owned Delaware incorporated subsidiary, G Medical Innovations USA Inc, has executed an agreement to acquire 100% of the outstanding membership interest of Telerhythmics LLC (Telerhythmics) (a Tennessee limited liability company), a US based cardiac diagnostic monitoring services provider. Telerhythmics, based outside Memphis, Tennessee, is a 24-hour cardiac diagnostic monitoring service used by hospitals and physician offices, and provides its monitoring services throughout the eastern region of the U.S. G Medical will acquire all the outstanding membership interests of Telerhythmics from NASDAQ listed imaging technologies company Digirad Corp (NASDAQ: DRAD) for a total up front consideration of US$1,950,000, subject to working capital adjustments. Completion of the agreement remains subject to the satisfaction of certain customary conditions precedent, including the receipt of any necessary consents from third parties including but not limited to government authorities. Telerhythmics, LLC., booked historical revenue from 1 January 2018 to 30 September 2018 of ~US$3.174M1 . The Telerhythmics acquisition, in addition to the Company’s acquisition of Cardiostaff Diagnostic Services Inc (as announced on 30 October 2017) will create a sizable player in the cardiac diagnostic US monitoring space, and in addition, provide G Medical with a solid base of business across the Southeast and Southwest territories. Telerhythmics is a Medicare and Medicaid designated IDTF (Independent Diagnostic Testing Facility) that provides physician practices and hospitals with arrhythmia monitoring services including mobile cardiac telemetry ("MCT"), cardiac event monitoring, Holter monitoring, and pacemaker analysis. The Telerhythmics acquisition will substantially increase insurance coverage and create a distinct competitive advantage, providing G Medical with ~100 commercial payor agreements across local, regional and national markets and an additional 30-35M covered lives (individuals insured); with the Company’s aggregated sum increasing to ~100M+ covered lives when considering existing G Medical Diagnostic Services payor agreements. Via the acquisition, G Medical will also gain access to several large health systems including Baptist, Ochsner, and HCA, and also to existing agreements in place with large insurance providers such as Blue Cross Blue Shield (BCBS), which has current reimbursement status for MCT (auto detect auto send) monitoring device. Further, Page 2 of 3 the Company’s regulatory approved medical devices will be translated to existing customers of both Telerhythmics and G Medical, providing for a superior technology offering and monitoring services when compared to traditional Holter monitoring. Telerhythmics, LLC., was established in 1996. It has long been recognized for superior clinical patient monitoring given its foundation of employing experienced critical care nurses. Telerhythmics’ business is synergistic and complementary to G Medical’s existing infrastructure and operations following the Company’s successful acquisition and integration of CardioStaff, and further increases the Company’s nationwide footprint and services for remote vital signs monitoring healthcare services across the US. Commenting on the latest acquisition, G Medical CEO Dr. Yacov Geva, said: “Acquiring Telerhythmics further strengthens our Company’s US footprint as we further focus our efforts to become a leader in complete (endto-end) and comprehensive vital signs medical monitoring and cardiac diagnostic services across the US. Telerhythmics brings additional payer contracts, clinical and commercial scalability, access to current monitoring technologies and an existing platform to launch our proprietary medical devices with the aim to further grow our market share in this important area of digital health delivery.” Cardiac diagnostic monitoring and remote vital signs monitoring healthcare services is a rapidly growing industry in the US and the Company is well positioned to become an emerging leader in the E-Health and Vital Signs Monitoring space. The Company continues its preparations towards the submission of its F-1 Registration Statement towards a Dual-Listing on the NASDAQ Stock Exchange, where a number of the Company’s peers are currently listed. About G Medical Products G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals. The ‘Prizma’ Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members. G Medical also offers a professional real-time patient continuous monitoring solution, G Medical’s Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings. - Ends - Contact: Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com Investor Relations Viriathus Australia Level 8/525 Flinders Street Melbourne VIC 3000 Telephone: +61 2 8667 5360 www.viriathus.com Media Enquiries Closer Communications David Wolf Tel: + 61 411 111 787 david@closer.com.au About G Medical Innovations G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com CE, FDA & CFDA Approval Granted for Guangzhou China Production Facility 2018-10-30T05:04:29Z ce-fda-cfda-approval-granted-for-guangzhou-china-production-facility October 30, 2018 – Sydney, Australia – Mobile and e-Health company G Medical Innovations Holdings Ltd (“G Medical” or the “Company”) (ASX: GMV) is pleased to announce it has successfully completed the independent audit process to achieve CE, FDA and CFDA regulatory approval for the Company’s Production Facility in Guangzhou China. The Company is proud to inform its shareholders that it achieved excellent results during the multistage independent audit process conducted during September and October for all three regulatory bodies (CE, FDA and CFDA). The full audit has now been completed, and the results of the audit are expected to be published and searchable to the public later this week via the following directory; https://www.sgsgroup.com.cn/en/certified-clients-and-products/certified-client-directory The Company expects to receive its final certification documentation from the Regulatory bodies within 3 weeks. This is a significant milestone for the Company which intends to utilise the full production capacity of its Guangzhou facility. As previously announced to the market, the Company has numerous agreements in place globally and the approvals granted for the Guangzhou Facility enables the Company to commence production and distribution to those territories which recognise CE, FDA and CFDA certification and have already granted regulatory approval for the Company’s medical devices. G Medical CEO Dr. Yacov Geva said, “We are very pleased to have achieved CE, FDA and CFDA approval, which exemplifies the high-quality of our Production Facility and our strong in-Country relationships. The Company has been committed to achieving this major milestone in record timeframes and we now look forward to being able to meet the demand from our global partnerships and rapidly execute our commercial plans.” G Medical has a strong pipeline of customer demand and the increased production capacity positions the Company to fulfil its expansion into the rapidly growing E-Health market. As the Company continues its preparations for the listing of its Chinese subsidiary, Guangzhou Yimei Innovative Medical Science and Technology Co. Ltd, on the main board of The Hong Kong Stock Exchange (HKSE), the granting of CE, FDA and CFDA approval was an important achievement in this process. The Company requests that its securities stay in trading halt, pending an announcement in respect of a convertible note capital raising and a material acquisition. The Company requests the trading halt until the market opens on 31 October 2018 or until the announcement is made, whichever is the earlier. Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com Investor Relations Viriathus Australia Level 8/525 Flinders Street Melbourne VIC 3000 Telephone: +61 2 8667 5360 www.viriathus.com Media Enquiries Closer Communications David Wolf Tel: + 61 411 111 787 david@closer.com.au About G Medical Innovations G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com G MEDICAL ENGAGES US UNDERWRITER TO MANAGE DUAL-LISTING ON NASDAQ 2018-10-01T23:22:12Z g-medical-engages-us-underwriter-to-manage-dual-listing-on-nasdaq October 2, 2018 – Sydney, AUSTRALIA - Mobile and e-Health company G Medical Innovations (ASX: GMV) (“G Medical” or the “Company”) has today engaged a New York based Underwriter, to assist in the processes towards a US Public Offering via the NASDAQ Stock Exchange. The Company will remain listed on the Australian Stock Exchange, and the management of G Medical have engaged an Underwriter who will now proceed with submission of the F-1 Registration Statement with all parties working towards a US listing within the next 4 to 5 months. G Medical cautions investors that there can be no certainty that the proposed US listing will proceed. Investors should note that the listing is subject to satisfaction of all legal and regulatory requirements with NASDAQ, SEC and ASX, as well as any shareholder approvals that may be required under the ASX Listing Rules. Shareholders will be updated throughout the process as appropriate, and the amount of capital to be raised will be determined closer to the proposed offering. -ENDS- Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com Investor Relations Viriathus Australia Level 8/525 Flinders Street Melbourne VIC 3000 Telephone: +61 2 8667 5360 www.viriathus.com Media Enquiries Closer Communications David Wolf Telephone: + 61 411 111 787 david@closer.com.au About G Medical Innovations G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com IMC19 brings the future of science into focus 2018-09-25T22:43:44Z imc19-brings-the-future-of-science-into-focus-1 Critical discoveries and research that will help to transform health, science and industry are set to be the lasting legacy of the 19th International Microscopy Congress (IMC19), according to leaders of the scientific world. Held every four years, IMC19 saw more than 2,100 of the world’s top scientists and researchers from 48 countries come together at ICC Sydney to network, collaborate and discover the latest high-tech instrumentation and systems in microscopy and microanalysis. IMC19 also inspired the next generation of young scientists with its Schools Outreach Program, which welcomed 570 students from 19 schools. The program also featured a “Young Scientists Assembly” where 50 young scientists from around the world enjoyed the opportunity to discuss career planning with some of the most senior figures in the field. Professor Simon Ringer, Congress Chair, said the impact of IMC19 would be revealed over time from the global scientific community. “Innovations in microscopy enable us to extend our understanding of ourselves and the world around us. IMC19 brought together leaders in both the development and the application of microscopy in a huge range of disciplines,” he said. “These connections will ultimately lead to breakthroughs, as researchers take the insights from advanced microscopy to develop a treatment for cancer, a vaccine for a virus, or a new 3D printed metallurgical alloy that improves our atmosphere by being strong and light and thereby fuel and greenhouse gas efficient.” The week-long scientific program included presentations by four expert plenary speakers, two Nobel Laureates, 150 invited presenters as well as 26 pre-congress workshops and 463 oral talks, bridging the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. The pioneering IMC19 Outreach Learning Program welcomed high school students to experience the very latest light and electron microscope equipment and a chance to meet with researchers and specialists in microscopy. Mrs Diane Fairweather, Head of Science, Riverstone High School, said the program allowed students to access cutting-edge technology. “This was a great STEM initiative by IMC19 and an amazing experience for the students who came. We don’t have these microscopes at our school and without the IMC19 Outreach Program, most of our students wouldn’t be able to use this equipment,” said Fairweather. “Our students are engaged; they are learning directly from experts on things like using the lens to focus – it’s a real hands-on experience.” The Outreach Program offered students access to the latest equipment including, VR, four scanning electron microscopes, 20 life microscopes and 3D printing. Equipment and demonstrations were supported by Zeiss, Leica, AXT, Keepad Interactive, NewSpec, ATA, Coherent, UNSW Art and Design and Me3D. Citing recent examples of some of the life-changing advancements that have developed as a direct result of microscopy, Dr Alan Finkel, Australia’s Chief Scientist, inspired the audience at IMC19 and set the scene for a week of breakthroughs in his opening address. “An investment in this field (microscopy) is an investment in nanoparticles that target such things as a drug directly to malignant cells; 3D printed lattices that act like tiny factories for T-cells; vital in the new generation of cancer immunotherapies and more,” said Dr Finkel. “Without Microscopy, there is no modern science – end of story.” Professor Paul Munroe, Congress Co-Chair, said IMC19 had laid the foundations for great things. “We are excited to see where the collaborations from IMC19 take the industry, and what new technology and research will be showcased at the next congress in Korea in 2022,” he said. For more information on IMC19 visit: http://imc19.com. IMC19 brings the future of science into focus 2018-09-25T22:34:39Z imc19-brings-the-future-of-science-into-focus Critical discoveries and research that will help to transform health, science and industry are set to be the lasting legacy of the 19th International Microscopy Congress (IMC19), according to leaders of the scientific world. Held every four years, IMC19 saw more than 2,100 of the world’s top scientists and researchers from 48 countries come together at ICC Sydney to network, collaborate and discover the latest high-tech instrumentation and systems in microscopy and microanalysis. IMC19 also inspired the next generation of young scientists with its Schools Outreach Program, which welcomed 570 students from 19 schools. The program also featured a “Young Scientists Assembly” where 50 young scientists from around the world enjoyed the opportunity to discuss career planning with some of the most senior figures in the field. Professor Simon Ringer, Congress Chair, said the impact of IMC19 would be revealed over time from the global scientific community. “Innovations in microscopy enable us to extend our understanding of ourselves and the world around us. IMC19 brought together leaders in both the development and the application of microscopy in a huge range of disciplines” he said. “These connections will ultimately lead to breakthroughs, as researchers take the insights from advanced microscopy to develop a treatment for cancer, a vaccine for a virus, or a new 3D printed metallurgical alloy that improves our atmosphere by being strong and light and thereby fuel and greenhouse gas efficient.” The week-long scientific program included presentations by four expert plenary speakers, two Nobel Laureates, 150 invited presenters as well as 26 pre-congress workshops and 463 oral talks, bridging the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. The pioneering IMC19 Outreach Learning Program welcomed high school students to experience the very latest light and electron microscope equipment and a chance to meet with researchers and specialists in microscopy. Mrs Diane Fairweather, Head of Science, Riverstone Highschool, said the program allowed students to access cutting-edge technology. “This was a great STEM initiative by IMC19 and an amazing experience for the students who came. We don’t have these microscopes at our school and without the IMC19 Outreach Program, most of our students wouldn’t be able to use this equipment,” said Fairweather. “Our students are engaged; they are learning directly from experts on things like using the lens to focus – it’s a real hands-on experience.” The Outreach Program offered students access to the latest equipment including, VR, four scanning electron microscopes, 20 life microscopes and 3D printing. Equipment and demonstrations were supported by Zeiss, Leica, AXT, Keepad Interactive, NewSpec, ATA, Coherent, UNSW Art and Design and Me3D. Citing recent examples of some of the life-changing advancements that have developed as a direct result of microscopy, Dr Alan Finkel, Australia’s Chief Scientist, inspired the audience at IMC19 and set the scene for a week of breakthroughs in his opening address. “An investment in this field (microscopy) is an investment in nanoparticles that target such things as a drug directly to malignant cells; 3D printed lattices that act like tiny factories for T-cells; vital in the new generation of cancer immunotherapies and more,” said Dr Finkel. “Without Microscopy, there is no modern science – end of story.” Professor Paul Munroe, Congress Co-Chair, said IMC19 had laid the foundations for great things. “We are excited to see where the collaborations from IMC19 take the industry, and what new technology and research will be showcased at the next congress in Korea in 2022,” he said. For more information on IMC19 visit: http://imc19.com. Images: IMC19 Outreach Learning Program: Notes to editors: Interviews with Professor Simon Ringer, Congress Chair, IMC19 Interviews with Professor Paul Munroe, Congress Co-Chair, IMC 19 Media enquires contact Zadro Sinead Andrews | Account Coordinator | Zadro 02 9212 7867 | sinead@zadroagency.com.au Elizabeth Williams | Group Account Director | Zadro 02 9212 7867 | elizabeth@zadroagency.com.au NOTE: About the 19th International Microscopy Congress, 9 – 14 September 2018 Held once every four years, the International Microscopy Congress (IMC) is the preeminent meeting for researchers, practitioners, decision makers, national microscopy societies, industry partners and stakeholders involved in microscopy sciences from all over the world. Now in its 19th year, IMC19 ‘Microscopy: Bridging the Sciences’ is the only platform to bring together international, national and local professionals to discover new opportunities, uncover findings, learn techniques, collaborate with peers, and network with global leaders in the field of microscopy. About the Australian Microscopy & Microanalysis Society (AMMS) The Australian Microscopy & Microanalysis Society (AMMS) is Australia’s industry association for the promotion, co-operation and development of microscopy, microanalysis, and related techniques across a broad range of scientific disciplines. About the International Federation of Societies for Microscopy (IFSM) The International Federation of Societies for Microscopy (IFSM) comprises microscopy societies from all around the world to contribute to the advancement of microscopy in all its aspects. Microscope that gets to the heart of matter 2018-09-10T03:41:58Z microscope-that-gets-to-the-heart-of-matter Two Nobel Laureates and the NSW Chief Scientist & Engineer will officially unveil a vital piece of scientific infrastructure at the University of Sydney at a special event. The Thermo Fisher Themis-Z transmission electron microscope (TEM) has the highest resolution of any microscope in Australia. Its addition to the University of Sydney will provide researchers with unparalleled access to the mysteries of the atomic structure of materials. The 4.5-metre tall microscope is housed in the purpose-built $150 million Sydney Nanoscience Hub in a room that is shielded from electromagnetic interferences and ‘floats’ architecturally independent from the building to minimise vibrations. The resolution of this analysis technique is breathtaking. The machine can obtain images with resolution better than 0.06 billionths of a metre (0.06 nanometres). That is about 10 times smaller than the distance between silicon atoms or five times smaller than the distance between carbon atoms in diamond. The microscope, which is available for industry as well, also has applications in geosciences, mining, chemical and mechanical engineering. The new NSW Chief Scientist & Engineer, Professor Hugh Durrant-Whyte will unveil the device in his first week of his official functions alongside two Nobel Laureates in Chemistry, Prof. Dan Shechtman, The Technion, Israel and Professor Joachim Frank, Columbia University, USA, who are visiting Sydney for the 19th International Microscopy Congress (IMC19), which is jointly hosted by the University of Sydney and UNSW. Event details: What: Sydney Microscopy and Microanalysis launch event Aberration-corrected Transmission Electron Microscope Where: Research Foyer, Sydney Nanoscience Hub, Physics Road, University of Sydney When: Tuesday, 11 September 2018. 1.45pm for 2pm start. The 19th International Microscopy Congress (IMC19), 9-14 September, at ICC Sydney, will centre around the theme, Microscopy: Bridging the Sciences, promoting collaboration across the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. Complimentary media passes to the launch event are available; apply by sending your name, position and publication title to sinead@zadroagency.com.au. Complimentary media passes to IMC19 are also available; apply by sending your name, position and publication title to sinead@zadroagency.com.au. Image: The Thermo Fisher Themis-Z transmission electron microscope (TEM) How many scientists does it take to look through a microscope? 2018-09-06T02:03:09Z how-many-scientists-does-it-take-to-look-through-a-microscope More than 2,000 of the world’s top scientific brains will explore new findings, share research, and experience the latest state-of-the-art scientific microscopy equipment helping to reinvent and expand human knowledge, in Sydney next week. Field emission guns and new electron exploration systems are two of the many innovations and leading advancements in medical science that will be on show when the world’s largest microscopic community descends on Sydney for the 19th International Microscopy Congress (IMC19). The event, held every four years, starts on 9 September and will see presentations by world-renowned thought leaders and Nobel Laureates Professor Dan Shechtman and Professor Joachim Frank, from The Technion Israel, who won the 2017 Nobel Prize in chemistry for his work as founder of the single-particle cryo-electron microscopy (cryo-EM). By bringing together experts working across a multitude of academic and industrial fields, IMC19 will showcase - and define - how clear, crisp microscopic magnification, helps advance life on Earth. The genesis of our future’s most significant discoveries including reproductive breakthroughs and a step towards a cure for cancer can be found at this world-famous science event and the multi-million-dollar equipment on display. Tek-Event, Sydney based manufacturer of equipment dedicated to the field of human and animal reproductive technologies (ART), will showcase its range of brand new technologies providing a safe environment for tissue observation. Dieter Regel, Sales Director, Tek-Event, commented on the increasing requirement to provide accurate temperature control as well as CO2 and humidity in the latest technologies advancing human IVF laboratories, animal research and veterinary ART facilities. “Researchers who have the requirement to view cells or tissue microscopically, are often challenged when their environment is not stable. TEK-Event are excited to showcase our latest Cell-Tek microscope chambers, which helps create a controlled environment for examination in many fields of research, including the handling of oocytes and embryos in ART,” said Regel. Thermo Fisher Scientific will offer attendees a chance to take part in live demonstrations with technical experts working in innovative software and automated microscopy products and showcase a wide range of microscopy solutions. Attendees can register for a learning lunch with ZEISS, to experience their innovative microscopy technologies and applications. Sessions will cover 3D electron microscopy; X-ray microscopy and analytical microscopy and guests can win a ZEISS VR One Plus virtual reality headset. Tek-Event, Thermo Fisher Scientific and ZEISS will be joined by over 60 other confirmed exhibitors at IMC19, including Jeol, Quorum Technologies, Tescan, Technoorg Linda Co Ltd, Delmic, Hitachi, Leica and Nano Technologies Solutions. Delegates will also enjoy a range of activities and a vibrant social program in conjunction with the congress, aimed to engage attendees and help spark new connections among the scientific community. The IMC19 Outreach Learning Program will host 21 schools across Australia, to offer students the chance to undertake four storyline-based challenges, featuring the latest light and microscopy equipment alongside leading researchers and instrument specialists. Microscopy Australia will present a unique exhibition during the congress, Stories & Structures - New Connections, bringing together microscopy and Indigenous art through visual and story-telling parallels. The exhibition will showcase 21 artworks and 24 micrographs, as well as feature live painting by Indigenous artist Kurun Warun in residence. The 19th International Microscopy Congress (IMC19), 9-14 September, at ICC Sydney, will centre around the theme, Microscopy: Bridging the Sciences, promoting collaboration across the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. P!nk on board with antibacterial range after son diagnosed with HFMD 2018-09-03T05:04:09Z p-nk-on-board-with-antibacterial-range-after-son-diagnosed-with-hfmd Wowing 37,000+ fans in Dunedin, NZ, on Saturday night, there were no signs of the recent health issues that have plagued international pop-rock star Pink (Alecia Moore) since arriving Down Under. Hospitalised with a gastric virus, Moore was forced to postpone three concerts in Sydney, only to find out her younger child, son Jameson, had been diagnosed with Hand-foot-and-mouth disease (HFMD), a highly contagious viral infection spread through the air or contact. With several shows remaining on her Beautiful Trauma tour in New Zealand and Australia, and Moore’s own low immunity after her illness, ZOONO® Marketing Manager Pip Hobson wanted to reach out and offer some assistance. ZOONO® are an ASX-listed, NZ-based company which has been quietly taking on the world over the last two decades. Their sought-after exclusive revolutionary technology has created an antibacterial range that is alcohol-free, non-toxic, safer for kids, plants and animals and kills 99% of nasties. Their skin products stay working for up to 24 hours, and surface products up to 30 days. The benefit of using ZOONO® products are that they are the ultimate in germ prevention – they kill 99.9% of germs, are long-lasting and offer preventative self-care unlike any other antibacterial range. “We asked our PR person to contact Pink’s team and offer to send some ZOONO® Hand Sanitiser, Microbe Shield Surface Wipes and Germ Foggers (similar to flea bombs for rooms, but for germs instead). Alecia is more susceptible to catching HFMD after being unwell in Australia, so we wanted to help out by sending out a large package of our antibacterial product as an extra line of defence against HFMD spreading to family and crew,” says Hobson. Pink’s team quickly came back with a resounding ‘Yes please!’ “Parents are usually very keen to try ZOONO® because it is non-toxic, water-based and gentle on skin. With a touring crew of over 80 people plus a young family, preventative self-care is key,” says Hobson. An urgent delivery was made to distribute to the star and her family, and the rest of the Beautiful Trauma Tour crew. Who Are ZOONO®? Because of their unique technology, ZOONO® products are sought-after by hospitals, laboratories, surgeries and food/beverage facilities all over the world. Originally launched as a commercial antibacterial range, demand led to the launch of their customer-focused range which has had huge uptake, with their alcohol-free Hand Sanitiser fast becoming a cult product. It is regularly touted by well-known Australasian Instagram influencers such as With The Whittakers, Just Another Mummy, The OCD by Christine and personalities such as Niki Bezzant (Healthy Food Guide magazine) and Ally McManus (Wellbeing magazine). ZOONO® has many customers around the world, such as CVS Pharmacy, Walmart and Amazon in the USA and MITIE in the UK who are supplying products and services to the likes of Rolls Royce, Land Rover Jaguar, banks and several airports throughout the UK. Fonterra’s head office in NZ, along with 400 local childcare centers in NZ and Australia, along with several household names in food manufacturing and processing also use ZOONO® products. ZOONO® is now used in several hospitals in South Korea and the Shimamura stores in Japan and have several new customers across the Middle East and India as the products are alcohol-free (Halal). With a headquarters in Auckland and offices in The United Kingdom, sells its products at 8,000 retail outlets in the USA and South Korea, including through Amazon in the US. They are currently experiencing significant growth in markets such as the UK and EU, Canada, the Middle East, China, Japan, ASEAN Countries and continue to sell in leaps and bounds throughout the United States. ZOONO® products are manufactured both in Auckland, New Zealand as well as South Carolina in the US. How Does ZOONO® Work? ZOONO® uses a molecule first developed by German scientists in the early 1900s to stop algae from building up on the hulls of submarines and ships. The molecule also effectively kills bacteria, viruses, fungi and mould, including Norovirus, making it an ideal solution in the prevention of germs spreading. "Independent third-party testing shows it is still killing bacteria at 99.24%, even after 24 hours," stated Zoono’s Chief Scientific Officer (CSO) Dr Andrew Alexander. The molecule destroys germs through a mechanical process rather than poisoning or dehydrating them, which makes it safe for children and pets, and environmentally friendly. ZOONO® 's unique technology kills by a 'mechanical‘ process rather than via poison or dehydration. A layer of positively charged molecular pins bonds to the surface and attracts then destroys negatively charged pathogens by rupturing the pathogen cell. The protective 'pins' on the surface remain intact and effective for up to 30 days. The germ cell is stopped dead in its tracks, the same way a balloon pops. ZOONO® CEO, Paul Hyslop says, "We’re a disruptive inventor. Our product works when it has dried, not just when it is wet. Our business model is to make much less product of a non-toxic variety, which is used sparingly but lasts a long time. In terms of preventing the spread of pathogens, our products are the gold standard, which is why so many hospitals, labs, childcare centres and food manufacturing customers choose ZOONO®. “However important building immunity is, not everyone has the time to get sick, or have the kids sick. ZOONO® offers an extra line of defence against a daily onslaught of germs. And as antibiotic resistance continues to rattle the medical industry worldwide, prevention is key to avoid pandemics," says Hyslop.   ZOONO® is exclusively sold online, at www.zoono.com and www.amazon.com.au. Priced from AUD$7.99 and NZD$9.99.   ZOONO® products are backed by science, and tested in independent, accredited, GLP Laboratories all around the world. ZOONO® products have been proven in over 100 laboratory tests to kill or deactivate a variety of bacteria, viruses, mould, fungi and algae. They are the original leaders in germ defence innovation worldwide. ENDS For more information or to request an interview, please contact Jodie Bennett: Jodie@digitalcitizens.co.nz  021 025 111 05 2018 ADIA Research Grant Tackles Periodontitis 2018-08-09T04:30:23Z unisyd-paper-on-gifts-and-the-dental-profession-misses-the-mark Pioneering research to address chronic periodontitis has been awarded the Australian Dental Industry Association Research Grant bestowed by the Australian Dental Research Foundation (ADRF), the nation’s leading funding body for early-career researchers into dental and oral health issues. The grant is funded by the Australian Dental Industry Association (ADIA), the peak business organisation representing innovative dental product manufacturers and suppliers. The most recent award was provided to Associate Professor Neil O’Brien-Simpson from the University of Melbourne Dental School into research associated with antimicrobial peptides that target periodontal pathogens. He’s a project manager for the Oral Health Cooperative Research Centre. The research project will be supported by Dr Jason Lenzo and Dr James Holden, both from the Melbourne Dental School. The research seeks to address chronic periodontitis, an inflammatory disease associated with a pathogenic subgingival bacteria leading to the destruction of the tooth’s supporting tissues and ultimately tooth loss. It is a major public health problem in all societies and is estimated to affect at least 30% of the adult population, including 5% to 6% who experience severe forms of the disease. The prevention of chronic periodontitis relies on removing the bacterial burden by effective tooth cleaning, sometimes in combination with antibiotics and / or antiseptics; however, long-term use of antibiotics is undesirable due to the emergence of resistant bacteria. Indeed, several reports have highlighted an increasing trend towards antibiotic resistance in oral bacteria. The increasing reports of multi-drug and antibiotic resistant bacteria and the limits on the use of antiseptics, such as chlorhexidine, have resulted in extensive research to discover and develop new and novel classes of antimicrobials that are effective and safe for human use. “The objectives of the research align with the conditions of the Australian Dental Industry Association Research Grant that provides funding for projects that may, following commercialisation, support the development of new and / or innovative dental and oral healthcare treatment pathways or products,” said Troy Williams, ADIA Chief Executive Officer. The Australian Dental Industry Association Research Grant provides funding to explore the potential of a novel class of antibiotics called antimicrobial peptides (AMP). The research team have already identified several AMPs by altering their sequence and adding chemical moieties that reduce toxicity to mammalian cells while targeting and enhancing antibacterial activity towards periodontal pathogens. “ADIA has a long track-record of supporting the development of innovative patient diagnostic and treatment options and it's in this context that we’re committed to the long-term funding of the Australian Dental Industry Association Research Grant is funded,” Mr Williams said. Ends. Photograph & Images — ■. Neil O'Brien Simpson - University of Melbourne [.JPG] Media Contact —ADIA Communications Officert: 1300 943 094.....m: 0450 013 446.....e: media@adia.org.au ADIA Background Information — Founded in 1925, the Australian Dental Industry Association (ADIA) is the peak business organisation representing innovative manufacturers and suppliers of dental products.  Active in each mainland state and with a strong presence in Canberra, ADIA is a strong advocate for policy reforms that allow member businesses to grow, create jobs and operate sustainably.  ADIA's vision is for an industry that empowers oral health professionals to advance the health and well-being of all Australians.  The services offered by ADIA that support member businesses include industry statistics, training programmes and trade shows including ADX Sydney, the nation's largest healthcare exhibition that attracts some 10,000 stakeholders from across the oral healthcare community. For further information on ADIA visit the website at:www.adia.org.au  G MEDICAL ENGAGES GLOBAL INVESTMENT BANK ‘UOB’ FOR PROPOSED LISTING OF CHINESE SUBSIDIARY ON MAIN BOARD OF HONG KONG STOCK EXCHANGE 2018-08-07T23:56:44Z g-medical-engages-global-investment-bank-uob-for-proposed-listing-of-chinese-subsidiary-on-main-board-of-hong-kong-stock-exchange Highlights: G Medical engages Global Investment Bank, UOB Kay Hian (Hong Kong) Ltd, as advisors to Hong Kong Initial Public Offering of its Chinese subsidiary Initial market capitalisation to be at least HK$1,500,000,000 (~A$260 million), as required by HKSE Listing Rules Mobile and e-Health company G Medical Innovations (ASX: GMV) (“G Medical” or the “Company”) has today announced its plan to list its Chinese subsidiary, Guangzhou Yimei Innovative Medical Science and Technology Co. Ltd, on the main board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange” or “HKSE”). Under the proposed listing, Guangzhou Yimei Innovative Medical Science and Technology Co., Ltd (“GYIMSTC Ltd”) would spin off from G Medical, with the Australian Securities Exchange Ltd (“ASX”) listed G Medical (“Parent Co”) to retain not less than a 50% ownership stake in the proposed Hong Kong Stock Exchange listed GYIMSTC Ltd. G Medical Parent Co currently owns 70% of GYIMSTC Ltd. The management of G Medical have appointed global Investment Bank, UOB Kay Hian (Hong Kong) Limited (“UOB”) to act as the financial adviser (the “Agreement”). UOB have committed to the proposed IPO in accordance with all minimum listing requirements of HKSE, with all parties working towards a listing within the next 6 to 9 months. G Medical cautions investors that there can be no certainty that the proposed IPO will proceed, and that the listing is subject to satisfaction of all legal and regulatory requirements in Australia and Hong Kong, including any shareholder approval that may be required under the ASX Listing Rules. Shareholders will be updated throughout the process as appropriate. Guangzhou Yimei Innovative Medical Science and Technology Co. Ltd oversees all China-based manufacturing for G Medical, ensures all local certifications are met, and has worked to build a strong relationship with the China Food and Drug Administration (CFDA). It was the first company in 2018 to be granted acceptance to the Green Channel expedited Guangdong Provincial CFDA regulatory approval process. This process was successfully applied to G Medical’s Prizma Medical Smartphone Case, and will play a crucial role in the global commercialisation of this product. Future innovative medical solutions currently in the development pipeline should also benefit from this process. Green Channel also ensures expedited future CFDA applications and delivers a reduction in local enterprise income tax from 25% down to 15%. Funds raised from this listing will provide substantial working capital and fuel the research and development of innovative mobile health solutions and enable continued investment into state-of-the-art manufacturing facilities. The amount of capital to be raised will be determined closer to the proposed IPO. Under the terms of the Agreement, UOB will obtain an in-principle approval from the Hong Kong Stock Exchange to proceed with the listing application, with the initial market capitalisation of GYIMSTC Ltd to be at least HK$1,500,000,000 (~A$260 million), as required under the Hong Kong Stock Exchange Listing Rules for biotech companies (Chapter 18A provisions). G Medical will also provide a submission to the ASX to determine the requirements to proceed with the proposed IPO of GYIMSTC Ltd. G Medical advises that it previously disclosed this potential IPO in its ASX announcement dated 22 May 2017 in respect of the joint venture agreement in China. G Medical CEO Dr. Yacov Geva said, “Our proposed listing of GYIMSTC Ltd on the Stock Exchange of Hong Kong Limited is an important step in our global growth ambitions, shows our continued investment in the Chinese market and delivers an important avenue through which to raise the capital required to continue to innovate and introduce world-leading mobile health monitoring solutions to global markets.” The Company has included its corporate structure below to exhibit where the proposed entity to be listed on the Hong Kong Stock Exchange, Guangzhou Yimei Innovative Medical Science and Technology Co. Ltd, lies within the corporate structure. Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com Investor Relations Viriathus Australia Level 8/525 Flinders Street Melbourne VIC 3000 Telephone: +61 2 8667 5360 www.viriathus.com Media Enquiries Closer Communications David Wolf Telephone: + 61 411 111 787 david@closer.com.au About G Medical Innovations G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com Exposing “serial killers”, Quasi-Periodic Materials, and Sub-particles at IMC19 Sydney 2018-08-06T04:14:11Z exposing-serial-killers-quasi-periodic-materials-and-sub-particles-at-imc19-sydney Examining ‘serial killer’ cells and their behaviour will be at the centre of leading Australian Immunologist, Dr Misty Jenkins’, plenary talk - Understanding Serial Killers: Investigating the Function of Cytotoxic T Lymphocytes using Microscopy’ at IMC19 in Sydney next month. Approximately 1,600 Australians are diagnosed with brain cancer each year. Dr Misty Jenkins, NHMRC RD Wright Fellow and Laboratory Head at Walter Eliza Hall Institute for Medical Research, is seeking to change that, and will share how microscopy is directing her research into fighting brain cancer. Ahead of the IMC19 Congress, Dr Jenkins shares how her research is using imaging to understand how killer T-cells in the immune system could be modified to develop a cure for brain cancer. “T-cells are like the snipers of the immune system, they take out very specific targets and throw grenades at them to make them blow up. These cells are genetically designed to kill cancer cells, and we image this process to uncover new insights into the behaviour of these engineered killers,” said Dr Jenkins. With a series of accolades including the L’Oréal for Women in Science Fellowship (2013) and the Westpac/Australian Financial Review Top100 Women of Influence Award (2016), Ballarat-born Dr Jenkins is a testament to the high calibre of scientists that will be representing Australia at the Congress. It is such an exciting time for science, and this is our chance to show the world the great work we are doing on our own shores. But it is also a rare and unique opportunity to collaborate with, learn from and share the stage with renowned scientists from across the globe,” said Dr Jenkins. Dr Jenkins will be joined by the world’s most prominent plenary speakers including: Nobel Laureate Professor Dan Shechtman, from Technion - Israel Institute of Technology, presenting on The Discovery of Quasi-Periodic Materials – The Role of TEM Associate Professor Jennifer Dionne, from Materials Science and Engineering at Stanford, USA, who recently featured on Oprah Winfrey’s list of “50 things that will make you say ‘Wow’!” with In Situ Visualisation of Photochemical Transformations at the Single and Sub-particle Level Professor Zhiwei Shan, from Xi’an Jiaotong University, China, who has published over 70 prestigious papers and presented more than 130 invited talks discussing Mechanical Testing Laboratory Inside TEM The 19th International Microscopy Congress (IMC19), 9-14 September, at ICC Sydney, will centre around the theme, Microscopy: Bridging the Sciences, promoting collaboration across the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. To register and for more information: http://imc19.com Image: Dr. Misty Jenkins, Walter Eliza Hall Institute for Medical Research, Australia Professor Dan Shechtman, The Technion, Israel Assoc. Prof. Jennifer Dionne, Stanford, USA Prof. Zhiwei Shan, Xi’an Jiaotong University, China How cannabis research revealed the Endocannabinoid System and its influence on homeostasis 2018-07-23T00:29:02Z how-cannabis-research-revealed-the-endocannabinoid-system-and-its-influence-on-homeostasis Medicinal cannabis, its use and benefits for illness and disease are still being appreciated, and with new legislation introduced in Australia to legalise the use and supply of medicinal cannabis means the spotlight is on the medical profession to see how this herbal medicine can treat chronic illness. Justin Sinclair, an Australian Pharmacognosist and Educator will share his insights at the upcoming A5M Medical Conference in Melbourne and present: Cannabis Phytochemistry and the Endocannabinoid System. For more than 15 years Justin’s research and experience spans several scientific disciplines, including cultivation, botany, plant genetics, ethnopharmacology, and analytical phytochemistry. As coordinator for the Australian Medicinal Cannabis Research and Education Collaboration at NICM Health Research Institute, Western Sydney University, Sinclair is an advocate for medicinal cannabis research and believes worldwide studies have proven medicinal cannabis has provided patients with significant health benefits. “In countries where cannabis is legal, where they have a standardised medical supply of cannabis, the majority of patients are utilising it to treat chronic pain. Studies have shown benefits for many other illnesses, such as intractable epilepsy (non-responsive to normal modern pharmacological treatment), and evidence from overseas countries has demonstrated that medicinal cannabis may reduce spasticity in multiple sclerosis, amongst other illnesses. “Years of research has discovered a broad ranging neuro-modulatory system involved in most facets of homeostasis. This system is known as the Endocannabinoid System and was revealed only through research conducted on the Cannabis genus,” acknowledged Mr Sinclair. Sinclair believes that this is one of the greatest scientific discoveries in the last 50 years, with ongoing research into the endocannabinoid system likely to elucidate our understanding of various human diseases, with existing research suggesting that the endocannabinoid system is one of the primary regulators of homeostasis in the body. Speaking at the A5M Medical Conference in Melbourne, Mr Sinclair will discuss the discovery of the Endocannabinoid System (ECS) with a focus on receptors, ligands and enzymes that are involved in this modulator of homeostasis within the body. The 12th Annual A5M Anti-Ageing & Aesthetic Conference will take place on Saturday 4 and Sunday 5 August 2018 delivering cutting-edge research into this new frontier at Sofitel Melbourne on Collins, with a Preconference Workshop on Friday, 3 August 2018. To register for the Conference, visit: www.a5m.net Western Sydney University’s NICM Health Research Institute (NICM) is Australia’s leader in integrative and complementary medicine research and policy. As an ERA 5 ranking institute, NICM is globally recognised for its world-class research and innovations in integrative and complementary medicine. An initiative of NICM, the Australian Medicinal Cannabis Research and Education Collaboration (AMCREC) brings together a highly skilled transdisciplinary team and state-of-the-art facilities, providing a platform for high-quality, independent research, education and consultancy services in medicinal cannabis. For more information about NICM Health Research Institute, visit: www.nicm.edu.au Hashtag: #A5MConf18 - ENDS - - ENDS - Media Contacts: For further information, images, interviews or industry commentary, please contact: Debbie Bradley, Group Account Director | +61 2 9212 7867 | debbie@zadroagency.com.au Julie Donovan, Senior Account Manager | +61 2 9212 7867 | julie@zadroagency.com.au Notes to editor: The AustralAsian Academy of Anti-Ageing Medicine (A5M) is committed to providing medical practitioners, pharmacists and allied health professionals with support and education about the latest evidence-based methods to improve patient outcomes as they age - both internal and external. A5M is currently about to celebrate its 12th Annual Conference, one of the longest running conferences of its kind, which will take place on Saturday 4th and Sunday 5th August at Sofitel Melbourne on Collins For more information on A5M visit: www.A5M.net Connect through social media channels: Facebook: /A5Meducation Twitter: /A5Meducation LinkedIn: /A5M MUNDIPHARMA SUPPORTS PIONEERING PROSTATE CANCER RESEARCH 2018-07-17T02:41:40Z mundipharma-supports-pioneering-prostate-cancer-research The 2018 Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship has been awarded to Dr Kate Mahon, Medical Oncologist at Chris O’Brien Lifehouse, providing $60,000 to support her research into prostate cancer. This is the fifth annual Clinical Research Fellowship to be awarded in partnership with the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) to support genitourinary cancer research. The Fellowship was previously awarded by Tolmar Australia, which was acquired by Mundipharma in February, along with exclusive Australian and New Zealand distribution rights for prostate cancer medications Eligard® Injection and Bi Eligard® cp combination therapy. Dr Mahon was announced as the recipient of the Fellowship surrounded by experts in the research and treatment of genitourinary cancers at the 2018 ANZUP Annual Scientific Meeting in Sydney. “I am so pleased that Mundipharma was able to continue this significant support for research that will deliver real improvements in the treatment and management of prostate cancer,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand. "Mundipharma is thrilled to be partnering with ANZUP to offer this Fellowship, which attracted a number of high quality applications from ANZUP’s multidisciplinary membership across Australia and from a range of institutions and professional groups.” "Dr Mahon is an accomplished researcher and I’m excited to see what can be achieved with this support.” Professor Ian Davis, Chair of ANZUP said Dr Mahon was a most deserving Fellowship recipient. “Dr Mahon’s project was a very strong one in an excellent field of applications. This is a novel approach to try to understand the behaviour of prostate cancer, which we hope might give better guidance for the treatment of these men in the future,” Professor Davis said. The Fellowship is intended for early and mid-career clinician-researchers of any health care discipline in genitourinary cancer research and provides funding for one year to the institution of the successful applicant. “Dr Mahon’s research is focussed on the search for biomarkers that will tell clinicians which drugs will be most effective for each patient ahead of time, and how their treatment should be sequenced,” Ms Orr said. “Ideally this will mean that a simple blood test could guide personalised prostate cancer therapy, helping clinicians give each individual patient the best possible chance.” Dr Mahon is a Movember Prostate Cancer Foundation of Australia Clinician Scientist Award recipient, with a post-doctoral research focus on the treatment of advanced prostate cancer. “The Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship will provide a fantastic opportunity to further my translational research goals, particularly in moving a blood-based biomarker into the clinic to directly help patients with advanced prostate cancer,” Dr Mahon said. Prostate cancer is the third most commonly diagnosed cancer in Australia, with one in seven men expected to be diagnosed before the age of 85. It is also the third most common cause of cancer death. About Mundipharma Mundipharma Pty Limited is a member of a global network of independent associated companies which are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include treatments for cancer, glaucoma, asthma, burns, wounds, skin irritations and the common cold. For more information please visit: www.mundipharma.com.au. For further information please contact: Rob Bates Communications Manager +61 422 196 238 Rob.Bates@mundipharma.com.au ® ELIGARD is a registered trademark. About ANZUP ANZUP is a cooperative cancer clinical trials group with over 1,300 members across Australia, New Zealand and internationally. ANZUP was established to bring together all the professional disciplines and groups involved in researching and treating urogenital cancers. ANZUP exists to conduct clinical trial research and to improve outcomes for people affected by these cancers. For information please visit: www.anzup.org.au For further information please contact: Michelle Bowers, Internal Communications Manager +61 415 098 485 michelle.bowers@anzup.org.au Medical Conference to Address Inner and Outer Health 2018-07-09T04:13:59Z medical-conference-to-address-inner-and-outer-health In August 2018, the AustralAsian Academy of Anti-Ageing Medicine (A5M) will host their 12th Annual Conference and Expo in Melbourne, presenting an unrivalled line up of Australian and international aesthetic, integrative and anti-ageing experts to build the bridge between inner and outer health. With the continued integration of evidence-based conventional medicine with the complementary and aesthetics industry and a rise in a multidisciplinary and holistic approach to patient care – the A5M Conference will provide a truly encompassing view for medical professionals to learn, discuss and drive the future of integrative medicine across Australasia. Delegates will hear from over 20 speakers discussing interventions for both internal and external causes of chronic conditions, while focusing on examining the impact that exercise and lifestyle, diet and nutrition, supplementation, hormonal/metabolic imbalance and genetic factors, have on the ageing process. EVENT DETAILS: WHAT: AustralAsian Academy of Anti-Ageing Medicine Annual Conference WHEN: Saturday 4th and Sunday 5th August 2018 TIME: 8:00am – 5:30pm WHERE: Sofitel Melbourne on Collins PRICE: Members: $1050; Non-members: $1250 WEBSITE: https://www.a5m.net/conference-information/2018-annual-conference The Conference covers a range of topics including: Connecting Inner and Outer Health Mitochondrial Dysfunction and Chronic Disease Telomeres, Cancer and Ageing Metabolic and Hormonal Health Issues Reversing Mild Cognitive Decline Brain Health Healthy ageing and wellbeing New Frontiers in Medicine: Medical Cannabis And much more! To register, visit: https://www.a5m.net/conference-information/a5m-annual-conference/2018-a5m-conference Hashtag: #A5MConf18 - ENDS - For further information, images, interviews or industry commentary, please contact: Debbie Bradley, Account Director | +612 9212 7867 | debbie@zadroagency.com.au Julie Donovan, Senior Account Manager | +612 9212 7867 | julie@zadroagency.com.au Notes to editor: The AustralAsian Academy of Anti-Ageing Medicine (A5M) is committed to providing medical practitioners, pharmacists and allied health professionals with support and education about the latest evidence-based methods to improve patient outcomes as they age - both internal and external. A5M is currently about to celebrate its 12th Annual Conference, one of the longest running conferences of its kind, which will take place on Saturday 4th and Sunday 5th August at Sofitel Melbourne on Collins For more information on A5M visit: www.A5M.net Connect through social media channels: Facebook: /A5Meducation Twitter: /A5Meducation LinkedIn: /A5M The role of A5M is to develop and promote all aspects of preventative, anti-ageing and integrative medicine among practitioners and the community A5M is dedicated to educating medical practitioners, allied healthcare professionals, scientist and researchers by providing training, certification and continuing education in preventative, integrative and anti-ageing medicine As the leading academic body of Anti-Ageing Medicine in AustralAsia, A5M offers Certification and access to a world-class Fellowship Program in Anti-Ageing, Regenerative and Functional Medicine with Metabolic Medicine Institute (MMI) and the American Academy of Anti-Ageing Medicine (A4M) The principles of A5M education and programs are based on scientific evidence based medicine, which involves the integration of the five pillars of ageing: diet and nutrition, supplementation, hormones, genetics and exercise and lifestyle